Maia Anderson –
Thursday, October 29th, 2020
Gilead reported better-than-expected third quarter results Oct. 28, increased by sales of remdesivir, CNBC reported..
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
Remdesivir produced $873 million in sales throughout the third quarter, primarily in the U.S., CNBC reported. Gileads total sales were $6.5 billion in the 3rd quarter, up $5.5 billion from in 2015 and greater than the $6.3 billion experts predicted..
More articles on pharmacy: Kroger-owned drug stores using in-store quick COVID-19 antibody testsEli Lilly inks $375M handle United States to supply COVID-19 antibody drugSunstar recalls gingivitis drug due to prospective bacterial contamination.
Read the full post here.
Remdesivir, which ended up being the very first drug to receive complete FDA approval to treat COVID-19 Oct. 22, drove Gileads income up by 17 percent from in 2015. The drugmaker has actually been offering remdesivir under the brand name Veklury..
Leaving out remdesivir, the companys total sales increased 2 percent, to $5.6 billion, compared to last years, according to CNBC..